Phase II oral dysplasia data for Onyx's CI-1042

In a Phase II trial of CI-1042 (ONYX-015) given as a weekly mouthwash in 10 patients with premalignant oral dysplasia, two patients showed resolution of evident dysplasia and 4 patients showed improve...